Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Other Current Liabilities

Last Annual Value

3.83M

3-Year CAGR

22%

5-Year CAGR

11%

10-Year CAGR

5%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Other Current Liabilities

TRML · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.83M
29.3%12.7%N/A 
17.91M
-24.1%33.1%N/A
19.45M
53.7%34.2%65.4%
14.01M
10.6%126.9%N/A
13.26M
9.0%22.6%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
24.18M
43.1%3.2%-0.2%
14.11M
94.9%70.2%N/A
103.06M
42.1%75.3%35.0%
7.37M
7.3%83.1%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98